Convatec partners with Beta Bionics on innovative iLet Bionic Pancreas system

24 May 2023

Convatec partners with Beta Bionics on innovative iLet Bionic Pancreas system

•        First and only, automated insulin-delivery system that determines 100% of all insulin doses
•        inset™ and contact™ detach infusion sets used for subcutaneous administration
•       Convatec is sole supplier for infusion set
•       Further proof of Convatec’s strength in infusion set technology

 

Convatec Group Plc (LSE:CTEC), a FTSE 100 global medical products and technologies company focused on solutions for the management of chronic conditions, is pleased to announce its partnership with Beta Bionics for the iLet Bionic Pancreas which has now been FDA 510(k) cleared and set for commercial launch. Convatec is the global leader in design and manufacturing of infusion set technologies and insertion devices for insulin pump treatment.

 

The iLet Bionic Pancreas is a pocket-sized, wearable medical device designed to autonomously dose insulin. This innovative device is the first of its kind to simplify the user experience by only requiring the user weight, the continuous glucose monitoring (CGM) sleep target and overall CGM target. Convatec is pleased to be part of this launch that aims to significantly improve diabetes management and the quality of life and convenience for people living with diabetes.

 

The iLet Bionic Pancreas uses inset™, and contact™ detach infusion sets for subcutaneous administration of insulin. The inset™ is an all-in-one infusion set with a built-in insertion device, that connects to iLet insulin delivery system on one end and the user’s infusion site on the other end. inset™ is equipped with a soft indwelling cannula and the contact™ detach comes with a thin stainless-steel needle. Both infusion sets use a kink-free infusion tubing, thus ensuring an uninterrupted insulin infusion, and a skin-friendly adhesive tape to secure the set firmly at the infusion site. Convatec will manufacture these sets at our production sites in Mexico.

 

Kjersti Grimsrud, President & Chief Operating Officer, Infusion Care said, “We are pleased to be a part of the iLet Bionic Pancreas system, a truly innovative offering that provides more choice for people with Type I diabetes.  Convatec has been committed to pioneering diabetes solutions for more than 30 years. This partnership further demonstrates the strength of Convatec’s technology and leadership in infusion solutions. We are delighted to have Beta Bionics in our line-up of professional insulin pump partners, who share our ethos of providing innovative and simplified medical device solutions to patients and healthcare professionals."

 

 The iLet was designed to alleviate the work of diabetes management in everyday life and nearly eliminate the expertise that has been required to set up and manage a traditional insulin pump. With the iLet, healthcare providers can spend less time with the technology and more time with their patient. The only input that is required to get started is the user’s weight — the iLet does the rest. There is no longer the need to figure out the complexities of carb counting, bolusing, correction factors, insulin-to-carb ratios, or pre-set basal rates.

 

 

 

Contacts

 

Analysts & Investors               Media

Kate Postans, Vice President, Investor Relations & Corporate Communications   Sheebani Chothani, Investor Relations & Corporate Communications Manager   Buchanan: Charles Ryland / Chris Lane

+44 (0) 7826 447807     +44 (0) 7805 011046 ir@convatec.com   +44 (0)207 466 5000

 

 

 

About Convatec

 

Pioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in advanced wound care, ostomy care, continence care and infusion care. With around 10,000 colleagues, we provide our products and services in almost 100 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention and protection of at-risk skin, to improved patient outcomes and reduced care costs. Group revenues in 2022 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more about Convatec, please visit http://www.convatecgroup.com

 

About Beta Bionics

Beta Bionics is a medical technology company focused on the design, development, and commercialization of its iLet Bionic Pancreas in both the insulin dosing (the iLet) and bihormonal configurations. The iLet Bionic Pancreas platform is designed to use adaptive, self-learning, control algorithms, together with continuous glucose monitoring and pump technology, to autonomously compute and administer doses of insulin and/or glucagon and mimic the body’s natural ability to maintain tight glycemic control.

Beta Bionics is a for-profit, public benefit corporation and Certified B Corporation. Since its founding in 2015, its mission has been to help improve health outcomes and the quality of life of children and adults living with diabetes and other conditions of glycemic dysregulation.